← Human Trials & Peer-Reviewed Studies
Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.
Plain-language guide to PMID 12425705 (2002): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 12425705
- Journal
- JAMA
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Blackman MR et al. (15 authors)
- DOI
- 10.1001/jama.288.18.2282
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To evaluate the effects of recombinant human GH and/or sex steroids on body composition, strength, endurance, and adverse outcomes in aged persons.
Who Took Part
By PubMed's age tags, the people studied were older adults and people over 80, both men and women.
A 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling US women (n = 57) and men (n = 74) aged 65 to 88 years recruited between June 1992 and July 1998.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Groups ran in parallel: each of the participants stayed in one arm throughout.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Body Composition, Diabetes Mellitus, Estradiol, Hematocrit, Hormone Replacement Therapy and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 16 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2002 (JAMA), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.